Smith & Nephew plc’s Neutral Rating Reaffirmed at JPMorgan Chase & Co. (SN.)
Smith & Nephew plc (LON:SN.)‘s stock had its “neutral” rating restated by stock analysts at JPMorgan Chase & Co. in a report issued on Friday, AnalystRatingsNetwork reports.
A number of other analysts have also recently weighed in on SN.. Analysts at Credit Suisse raised their price target on shares of Smith & Nephew plc (LON:SN.) from GBX 750 ($12.01) to GBX 775 ($12.41) in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Societe Generale cut their price target on shares of Smith & Nephew plc (LON:SN.) from GBX 695 ($11.13) to GBX 660 ($10.57) in a research note to investors on Monday, September 9th. They now have a “sell” rating on the stock. Finally, analysts at Numis Securities Ltd reiterated an “add” rating on shares of Smith & Nephew plc (LON:SN.) in a research note to investors on Monday, September 2nd. They now have a GBX 870 ($13.94) price target on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. Smith & Nephew plc has an average rating of “Hold” and a consensus target price of GBX 775.38 ($12.42).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.